88 results about "Modifying genes" patented technology

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of a wheat transcription factor TaWRKY22 and a coding gene thereof in regulation and control of plant stripe rust resistance. The function of the wheat transcription factor TaWRKY22 is researched through molecular biology and genetics methods, it is found that knockout of the TaWRKY22 gene significantly improves the resistance of wheat to stripe rust, overexpression of the TaWRKY22 gene reduces the resistance of wheat to stripe rust, and then it is indicated that the wheat transcription factor TaWRKY22 plays a negative regulation role in wheat stripe rust resistance. Therefore, the TaWRKY22 gene is subjected to targeted modification through a gene editing technology, a new genetic material and a molecular breeding strategy can be provided for wheat stripe rust resistance breeding, and an important material and technical support are provided for breeding of wheat disease-resistant varieties.

The invention discloses a construction method and application of a chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain, the construction method comprises the following steps: carrying out gene modification on sweeteners Thaumatin and Brazzein, optimizing preference codons of chlamydomonas reinhardtii to synthesize CrThaumatin and CrBrazzein encoding genes, cloning the encoding genes into an expression vector pGM6, introducing the recombinant expression vector into a chlamydomonas reinhardtii wild-type chlamydomonas sp. Algal strain, and carrying out high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii. And screening by using a paromomycin resistance marker carried by the expression vector to successfully obtain an engineering algal strain. According to the present invention, the engineering strain is subjected to fermentation production to obtain the dry and stable Chlamydomonas reinhardtii powder rich in the target sweet protein, and the protein purification oral test results show that the sweet taste of the Chlamydomonas reinhardtii powder is 3-5 times of the sweet taste of the natural Thaumatin and Brazzein protein;

Disclosed are compositions, methods, and kits for modifying DNA within cells as well as compositions and methods for modifying gene expression in a cell. In particular, the invention generally relates to compositions, methods, and kits for DNA editing using single-stranded DNA. Compositions and methods for modifying gene expression using artificial microRNAs (amiRNA) are also contemplated.

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.

The present invention addresses the problem of providing a technique capable of haploid induction by enhancing the expression and / or function of a regulatory gene. The problem is solved by the use of a modified plant comprising an introduced or modified H2A.W gene, wherein said introduction or modification enhances the expression and / or function of the H2A.W gene in a germ cell.

Compositions and methods for inducing a double-stranded break (DSB) within the LPA gene, and / or modifying the LPA gene are provided. Compositions and methods for treating diseases associated with LPA are provided.

The invention discloses a primer group, a kit and a detection system for thalassemia gene detection. In order to more comprehensively and accurately detect point mutation, small insertion, small deletion, gene fusion mutation, large fragment deletion and gene structure variation on a thalassemia core gene and a modified gene in single detection, the invention provides a thalassemia gene detection primer group and a kit. Based on third-generation sequencing platforms such as a single-base nanopore sequencing platform and the like, all point mutation, small insertion, small deletion and gene fusion mutation in the amplification range of the thalassemia core gene and the modified gene can be detected by utilizing the primer group or the kit; and 60 alpha large fragment deletion mutations, 60 beta large fragment deletion mutations and 7 gene structure variations. The method is beneficial to rapid and comprehensive screening of thalassemia, and is high in detection sensitivity and good in accuracy.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated NA vaccine compositions and viral vaccine compositions that encode an Infectious Bronchitis Virus (IB V) spike (S) protein, an IBV nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against IBV or to vaccinate the subject against IBV.

Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and / or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cms1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided. Compositions comprise DNA constructs comprising a promoter that is operable in the cells of interest operably linked to nucleotide sequences that encode a mutated Cms1 protein with an abolished ability to produce DSBs, optionally linked to a domain that regulates transcriptional activity. The methods can be used to up- or down-regulate the expression of genes at predetermined genomic loci.

The invention relates to the technical field of plant genes, in particular to a histone demethylase gene OsJMJ708 for regulating and controlling rice salt stress toughness and application, and the histone demethylase gene OsJMJ708 comprises the following steps: obtaining an OsJMJ708 mutant; identifying an editing target spot of the OsJMJ708 gene; the OsJMJ708 is planted in a water planting mode; carrying out salt stress tolerance identification on the OsJMJ708 mutant; a homozygous silent mutant genetic material is obtained based on a gene editing technology by taking a rice histone methylation modified gene OsJMJ708 as a target gene. And salt stress treatment is carried out by using 180mM NaCl. The result shows that after salt stress treatment, the OsJMJ708 knockout mutant shows a salt-tolerant phenotype. It is proved that the OsJMJ708 gene plays a negative regulation role in the rice salt stress process, and excellent gene information is provided for rice salt-alkali tolerance oriented molecular design breeding.

The invention belongs to the technical field of gene engineering and enzyme engineering, and particularly relates to a high-temperature-resistant phytase mutant as well as a preparation method and application thereof. The 19 , 104 and 305 genes of a phytase gene appA are modified to obtain a plurality of high-temperature-resistant phytase mutants, the heat resistance of the three mutants G19P / G104P / D305R is remarkably superior to that of wild type and traditional phytase, experimental results show that after the phytase mutants are respectively treated for 20 minutes at the high temperature of 80 DEG C, 90 DEG C and 100 DEG C, the residual rates of enzyme activity are respectively 94.6%, 91.8% and 66.5%, and the residual rates of enzyme activity are respectively 94.6%, 91.8% and 66.5%. The phytase can completely tolerate granulation at the high temperature of 80-95 DEG C in the feed industry, and the industrial pain point of insufficient enzyme activity after traditional phytase granulation is greatly solved.

Isolated or purified antisense oligomers, combinations, and cocktails for modifying premRNA splicing or mRNA translation in the SOST gene transcript or a portion thereof to induce downregulation of functional SOST protein production. Isolated or purified antisense oligomers are provided, as needed, for inducing the production of proteins with retained or partially retained introns, truncated proteins, proteins lacking functional regions, or a reduction in the total amount of protein produced.

Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression. Methods for introducing compositions into cells and the use of the resultant cells in adoptive cell therapies are also provided.

The present invention relates to a modified CCA gene which encodes a CCA-adding enzyme, which modified CCA gene leads to resistance against a positive-strand RNA virus having a transfer RNA-like structure (TLS). The invention further relates to plants and seeds comprising the modified genes, methods for making and identifying such plants and use of the gene.

This invention discloses the application of chloroquine in improving gene editing efficiency. Specifically, it provides a novel use for chloroquine: enhancing the gene editing efficiency of gene editing reagents on recipient biological materials. The gene editing reagent is a gene editing tool plasmid. No prior art studies have combined chloroquine with gene editing efficiency. The inventors of this invention have discovered that treating recipient biological materials with chloroquine before transfecting them with gene editing reagents can significantly improve gene editing efficiency. This invention is simple to operate, widely applicable, and opens up a new avenue for improving editing efficiency by introducing exogenous small molecules rather than directly modifying gene editing tools.

The invention discloses application of hydroxychloroquine to improvement of gene editing efficiency. The invention provides novel application of hydroxychloroquine, namely application of hydroxychloroquine in improving gene editing efficiency of a gene editing reagent on a receptor biological material. In the prior art, a research of combining hydroxychloroquine and gene editing efficiency is not seen. The inventor of the invention finds that the gene editing efficiency can be remarkably improved by treating a receptor biological material with hydroxychloroquine and then transfecting a gene editing reagent. The method is easy and convenient to operate and wide in applicability, and a new way for improving the editing efficiency is developed by introducing exogenous small molecules instead of directly modifying a gene editing tool. The invention provides a basis for exploring an editing efficiency improvement strategy by adding exogenous molecules instead of modifying an editor mutant.

Methods for modifying a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising conditional by inversion elements. Methods are provided which afford the ability in a single targeting step to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a conditional by inversion element. Introduced alleles comprise pairs of cognate recombinase recognition sites, an actuating sequence and / or a drug selection cassette, and a nucleotide sequence of interest, and a conditional by inversion element, wherein upon action of a recombinase a conditional allele with a conditional by inversion element is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a conditional by inversion element in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.

Provided in the present disclosure is a composition for treating primary hyperoxaluria (PH). The composition provided by the present disclosure comprises a CRISPR-Cas system comprising a nuclease and a guide RNA for modifying a HAO1 gene. Further provided is a method for implementing treatment by administering a HAO1 gene-targeting system or a nucleic acid encoding same to a subject afflicted with a disease associated with primary hyperoxaluria (PH).

The present disclosure relates to the field of biomedicine, and in particular to a preparation method for and a use of an aging animal model. The present disclosure provides a method for preparing an aging animal model, comprising modifying genes in immune cells in an animal body, wherein the modification reduces or eliminates the function or level of Abhd5.

The invention belongs to the field of biological medicine, and relates to a preparation method and application of a metabolic syndrome animal model. The invention provides a preparation method and application of a metabolic syndrome animal model, the preparation method comprises the step of modifying genes in immune cells in an animal body, and the modification reduces or eliminates the function or level of Abhd5 in Treg cells.

The present invention relates to methods of generating one or more transgenic cells using circular single stranded DNA (CiSSD) as a donor template, as well as target genome modification. The methods include transferring one or more DNA polynucleotides into a cell for site-specific nuclease-mediated DNA repair, and selecting one or more cells into which the transferred DNA is introduced in the genome of the cell.

Provided herein are technologies for framing and evaluating biological sequence-based analysis tasks in a unified, natural-language-based, text in and text out format. Among other things, methods and systems of the present disclosure provide machine-learning technologies for combining biological sequence data, representing, for example, DNA, RNA, and protein sequences, with natural language, conversational style prompts that set out particular analysis tasks to be performed on the biological sequence data. This approach, for example, allows complex analysis tasks, including, but not limited to, identification of various sequence modifications, genes, and regulatory elements in DNA sequences, and quantification of properties such as degradation propensity of RNA and protein stability, to be input to a machine learning model in a uniform text-based format and for output to be generated in a same, unified, text-based format.

This disclosure provides modified AAV vectors for expressing tripeptidyl peptidase 1 (TPP1) in objects. Some aspects of this disclosure provide modified adeno-associated virus 1 (AAV1) vectors comprising a capsid protein containing a targeting peptide and a nucleic acid molecule containing a sequence encoding a modified AAV genome, said modified AAV genome comprising a replication (rep) gene, a capsid (cap) gene, and a tripeptidyl peptidase 1 (TPP1) transgene.

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and / or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and / or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin and / or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and / or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and / or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

This disclosure relates to type II Cas proteins, the CRISPR-Cas system, and their various uses. Type II Cas proteins extend the utility of the CRISPR-Cas system for targeting or modifying genes.

This disclosure relates to modified guide RNAs having improved in vitro and in vivo activity in genome editing methods. In some embodiments, the present disclosure provides compositions and methods for modifying a PCSK9 gene. In some aspects, the present disclosure provides a guide RNA, compositions thereof, and pharmaceutical compositions comprising a guide RNA or a composition as described herein. In some aspects, the present disclosure also provides uses and methods of using a guide RNA, a composition thereof, or a pharmaceutical composition as described herein, for inducing a double-strand break or a single-strand break in a PCSK9 gene, for reducing expression of a PCSK9 gene in a cell or subject, and for treating a patient having or at risk of having a PCSK9-related disease or condition.

Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression. Methods for introducing compositions into cells and the use of the resultant cells in adoptive cell therapies are also provided.

Provided herein are recombinant adeno-associated virus (rAAV) particles encoding microRNAs targeting the glucocorticoid receptor (GR) pathway, and in particular a microRNA17-92 (miR 17-92) cluster, and genes of interest. The modified genomes of these rAAV particles comprise heterologous nucleic acid sequences encoding microRNA structures. These particles exhibit enhanced transduction efficiencies in mammalian cells. Also provided herein are compositions of nucleic acids encoding the miR 17-92 cluster and nucleic acids encoding a gene of interest. Further provided herein are methods for administering these nucleic acid compositions to enhance transduction efficiencies.